Eyenovia to end eye drug study, cut 50% of its workforce
(Reuters) -Eyenovia said on Friday it will discontinue a late-stage study for its experimental drug-device combination to ...
Eyenovia to end eye drug study after missing late-stage goal, shares fall
(Reuters) -Eyenovia will discontinue a late-stage study for its experimental drug-device combination to treat ...
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating ...
BioSpace2d
Eyenovia Shares Plummet 70% After It Drops Lead Program
Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...
devdiscourse23m
Health Challenges and Innovations: A Global Overview
Recent health news highlights include CareMax filing for Chapter 11 restructuring due to significant debts, a severe dengue ...
Eyenovia Provides Update on Phase 3 CHAPERONE Study
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy ...
Eyenovia Third Quarter 2024 Earnings: Misses Expectations
Revenue missed analyst estimates by 99%. Earnings per share (EPS) also missed analyst estimates by 3.1%. Looking ahead, ...
Eyenovia to Cut 50% of Workforce After Phase 3 Study Disappoints
Eyenovia said Friday it plans to cut half of its workforce after results from a Phase 3 study missed their primary endpoint. The pharmaceutical company had 57 full-time employees as of March 15. There ...
Eyenovia Shares Plumb New Depths After Study Failure
Eyenovia said it is ending the Phase 3 study of a drug-device combination of low-dose atropine in its Optejet dispensing platform in pediatric progressive myopia and exploring its strategic options ...
Eyenovia plans to terminate Phase 3 CHAPERONE study after DRC review
Eyenovia (EYEN) announced that a review of the CHAPERONE data by an independent Data Review Committee found that the trial is not meeting its ...
devdiscourse8h
New Health Crisis Alerts: Dengue Surge, Mpox in California, and More
The latest health brief highlights a severe dengue outbreak in Bangladesh, California's first Clade I Mpox case, and Oregon's ...
Eyenovia, Inc.: Eyenovia Provides Update on Phase 3 CHAPERONE Study
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to discontinue study, review full data set, and eval ...